Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) – Pipeline Review, H2 2016’, provides in depth analysis on Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted pipeline therapeutics.

The report provides comprehensive information on the Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E)

The report reviews Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics and enlists all their major and minor projects

The report assesses Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

eFFECTOR Therapeutics, Inc.

Ionis Pharmaceuticals, Inc.

Onconova Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Overview 6

Therapeutics Development 7

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Stage of Development 7

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Therapy Area 8

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Indication 9

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Companies 12

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Universities/Institutes 14

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 19

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Companies Involved in Therapeutics Development 21

eFFECTOR Therapeutics, Inc. 21

Ionis Pharmaceuticals, Inc. 22

Onconova Therapeutics, Inc. 23

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Drug Profiles 24

4EGI-1 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

briciclib sodium - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

ISIS-EIF4ERx - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

SBI-756 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecule to Inhibit eIF4E for Oncology - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Dormant Projects 31

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Discontinued Products 32

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Featured News & Press Releases 33

Nov 24, 2015: Scientists identify promising new melanoma drug 33

Oct 29, 2015: Onconova Therapeutics to Present New Data on Briciclib at 2015 AACR-NCI-EORTC Meeting 34

Apr 21, 2015: Onconova Therapeutics Highlights Briciclib at the 2015 American Association of Cancer Research (AACR) Annual Meeting 34

Jan 04, 2011: Isis Initiates Phase II Lung Cancer Trial With ISIS-EIF4ERx In Combination With Carboplatin And Paclitaxel 35

Feb 01, 2006: Lilly Initiates Clinical Trials On Second Cancer Drug Discovered In Isis Collaboration 36

Jun 24, 2002: Expansion Of Antisense Agreement Between Isis And Eli Lilly 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by eFFECTOR Therapeutics, Inc., H2 2016 21

Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 22

Pipeline by Onconova Therapeutics, Inc., H2 2016 23

Dormant Projects, H2 2016 31

Discontinued Products, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports